Janux Therapeutics (JANX) Treasury Shares (2020 - 2021)

Janux Therapeutics (JANX) has reported Treasury Shares for 5 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares rose 92.53% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (up 92.53% YoY), while the FY2025 annual figure was $704869.0, up 106.19% from the prior year.
• Treasury Shares climbed to $1.2 million in Q1 2026 per JANX's latest filing, from $704869.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $1.2 million in Q1 2026 and bottomed at $17500.0 in Q2 2024.
• Historically, Treasury Shares has averaged $538778.8 across 3 years, with a median of $651299.5 in 2025.
• Annual changes were most pronounced in 2025 — Treasury Shares soared 3909.44% — and 2026, when it jumped 92.53%.
• Janux Therapeutics' Treasury Shares stood at $341847.0 in 2024, then soared by 106.19% to $704869.0 in 2025, then surged by 64.74% to $1.2 million in 2026.
• Business Quant data shows JANX's Treasury Shares at $1.2 million in Q1 2026, $704869.0 in Q4 2025, and $699467.0 in Q3 2025.